Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC).

Saltos, AN; Tanvetyanon, T; Williams, CC; Haura, EB; Creelan, BC; Antonia, SJ

JOURNAL OF CLINICAL ONCOLOGY, 2018; 36 (15):